Drugs / exosomes derived from mesenchymal stem cells
exosomes derived from mesenchymal stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03437759 | Mar 2017 → May 2018 | macular holes | Tianjin Medical University | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | exosomes derived from mesenchymal stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03437759 ↗ |
| Known as | exosomes derived from MSCs | “Exosomes derived from MSCs ameliorate retinal laser injury partially by inhibition of MCP-1.” PMID 27686625 ↗ Sep 2016 |
| Known as | MSC-derived exosomes | “Recently, MSC-derived exosomes (MSC-Exos), a type of microvesicle released from MSCs, were thought to carry functional proteins and RNAs to recipient cells and play therapeutic roles.” PMID 27686625 ↗ Sep 2016 |
| Known as | MSC-Exo | “Biological: exosomes derived from mesenchymal stem cells (MSC-Exo)” NCT03437759 ↗ |
| Known as | MSC-Exos | “Recently, MSC-derived exosomes (MSC-Exos), a type of microvesicle released from MSCs, were thought to carry functional proteins and RNAs to recipient cells and play therapeutic roles.” PMID 27686625 ↗ Sep 2016 |
| Action | Inhibit | “Collectively, these results suggest that MSC-Exos ameliorate laser-induced retinal injury partially through down-regulation of MCP-1.” PMID 27686625 ↗ Sep 2016 |
| Modality | Other / unclassified | “Recently, MSC-derived exosomes (MSC-Exos), a type of microvesicle released from MSCs, were thought to carry functional proteins and RNAs to recipient cells and play therapeutic roles.” PMID 27686625 ↗ Sep 2016 |
| Route | Intravitreal | “MSC or MSC-Exo intravitreal injection” NCT03437759 ↗ |